Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways

Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways

Bicyclol has been approved as an anti-inflammatory, hepatoprotective drug in China to treat various forms of hepatitis. However, the role of bicyclol in non-alcoholic fatty liver disease (NAFLD) is unknown. In this study, NAFLD model was established by feeding mice with high fat diet (HFD) for 16 we...

Full description

Bibliographic Details
Main Authors: Weixin Zhao, Yixiao Yan, Zhongxiang Xiao, Meihong Wang, Mingjiang Xu, Zhe Wang, Yi Wang, Zaishou Zhuang, Daona Yang, Gaozhi Chen, Guang Liang
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Bicyclol
NAFLD
Inflammation
MAPKs
NF-κB
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221006569

Internet

http://www.sciencedirect.com/science/article/pii/S0753332221006569

Similar Items